These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 23627783)

  • 1. Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin.
    Bogenschutz MP
    Curr Drug Abuse Rev; 2013 Mar; 6(1):17-29. PubMed ID: 23627783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses.
    Bogenschutz MP; Pommy JM
    Drug Test Anal; 2012; 4(7-8):543-55. PubMed ID: 22761106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classic hallucinogens in the treatment of addictions.
    Bogenschutz MP; Johnson MW
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():250-8. PubMed ID: 25784600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 7. [Classic psychedelic drugs and their potential therapeutic effect].
    Bayat M
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics and Personality.
    Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
    ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
    Bogenschutz MP; Forcehimes AA; Pommy JA; Wilcox CE; Barbosa PC; Strassman RJ
    J Psychopharmacol; 2015 Mar; 29(3):289-99. PubMed ID: 25586396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.
    Krebs TS; Johansen PØ
    J Psychopharmacol; 2012 Jul; 26(7):994-1002. PubMed ID: 22406913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
    Ezeaka UC; Kim HJJ; Laprairie RB
    Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).
    Nichols DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2331-2343. PubMed ID: 29461039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelics as Medicines: An Emerging New Paradigm.
    Nichols DE; Johnson MW; Nichols CD
    Clin Pharmacol Ther; 2017 Feb; 101(2):209-219. PubMed ID: 28019026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of cluster headache to psilocybin and LSD.
    Sewell RA; Halpern JH; Pope HG
    Neurology; 2006 Jun; 66(12):1920-2. PubMed ID: 16801660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.
    Yaden DB; Berghella AP; Regier PS; Garcia-Romeu A; Johnson MW; Hendricks PS
    Int J Drug Policy; 2021 Dec; 98():103380. PubMed ID: 34329952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.